

Title (en)

NOVEL FORMULATIONS WHICH STABILIZE LOW DOSE ANTIBODY COMPOSITIONS

Title (de)

NEUE FORMULIERUNGEN, DIE NIEDRIG DOSIERTE ANTIKÖRPER-ZUSAMMENSETZUNGEN STABILISIEREN

Title (fr)

NOUVELLES FORMULATIONS PERMETTANT DE STABILISER DES COMPOSITIONS D'ANTICORPS À FAIBLE DOSE

Publication

**EP 3688033 A4 20210623 (EN)**

Application

**EP 18861358 A 20180928**

Priority

- US 201762565178 P 20170929
- IB 2018057565 W 20180928

Abstract (en)

[origin: US2019099489A1] The present invention addresses an ongoing need in the art to improve the stability of antibody compositions. The invention broadly relates to novel formulations which stabilize and inhibit protein adsorption of low dose antibody compositions in a container means comprising a coating. More particularly, the invention described hereinafter, addresses a need in the art for formulations which stabilize and inhibit protein adsorption of low dose antibody compositions which are processed, developed, formulated, manufactured and/or stored in container means such as tormentors, bioreactors, vials, flasks, bags, syringes, rubber stoppers, tubing and the like.

IPC 8 full level

**A61K 9/00** (2006.01); **A61J 1/00** (2006.01); **A61K 9/08** (2006.01); **A61K 39/395** (2006.01); **A61K 47/02** (2006.01); **A61K 47/12** (2006.01); **A61K 47/18** (2017.01); **A61K 47/22** (2006.01); **A61K 47/26** (2006.01); **C03C 17/00** (2006.01); **C07K 16/28** (2006.01); **C23C 16/00** (2006.01)

CPC (source: EP US)

**A61K 9/0019** (2013.01 - EP US); **A61K 9/08** (2013.01 - EP US); **A61K 39/39591** (2013.01 - US); **A61K 47/02** (2013.01 - EP US); **A61K 47/12** (2013.01 - EP US); **A61K 47/183** (2013.01 - EP US); **A61K 47/22** (2013.01 - EP US); **A61K 47/26** (2013.01 - EP US); **B65D 65/42** (2013.01 - US); **C07K 16/2803** (2013.01 - EP); **C07K 16/2809** (2013.01 - EP US); **A61K 2039/54** (2013.01 - US); **C07K 2317/31** (2013.01 - EP US); **C07K 2317/76** (2013.01 - US); **C07K 2317/94** (2013.01 - EP US)

Citation (search report)

- [X] EP 1232753 A1 20020821 - CHUGAI PHARMACEUTICAL CO LTD [JP]
- [E] EP 3686217 A1 20200729 - GLAXOSMITHKLINE IP NO 2 LTD [GB]
- [A] SORINA MORAR-MITRICA ET AL: "Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration", MABS, vol. 7, no. 4, 14 June 2015 (2015-06-14), US, pages 792 - 803, XP055516367, ISSN: 1942-0862, DOI: 10.1080/19420862.2015.1046664

Citation (examination)

- EP 2237038 A1 20101006 - BECTON DICKINSON CO [US], et al
- See also references of WO 2019064263A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

**US 2019099489 A1 20190404**; EP 3688033 A1 20200805; EP 3688033 A4 20210623; JP 2020535181 A 20201203; MA 50670 A 20200805; US 2022202937 A1 20220630; WO 2019064263 A1 20190404

DOCDB simple family (application)

**US 201816145324 A 20180928**; EP 18861358 A 20180928; IB 2018057565 W 20180928; JP 2020517815 A 20180928; MA 50670 A 20180928; US 202117503759 A 20211018